HILLSIDE, N.J., May 25, 2006 /PRNewswire-FirstCall via COMTEX/ -- AgroLabs, Inc., a wholly- owned subsidiary of Integrated BioPharma, Inc. (INB) , announced today that Costco will be selling AgroLabs' proprietary Acai Extreme Energy product at more than 300 Costco wholesale stores throughout the United States beginning June 1, 2006.
Kurt E. Cahill, Chief Operating Officer of AgroLabs, said, "Costco is another strong partner to AgroLabs, which also carries our Naturally Noni, Naturally Pomegranate and Naturally Thai Mangosteen nutritional supplements. The addition of Acai Extreme Energy Formula to our product line offered by Costco is another key element in building and solidifying our relationship with Costco. We continue to work with Costco and our other key customers to cultivate the Company's name recognition as a leading provider of healthful nutritional products."
AgroLabs, Inc. distributes and markets healthful nutritional products under the following brands: Naturally Aloe, Naturally Noni, Naturally Pomegranate, Naturally Thai Mangosteen and most recently, Acai Extreme Energy. These products are distributed nationwide through major mass market, grocery, drug and vitamin retailers. Additional information on AgroLabs and its products can be obtained from its website at http://www.agrolabs.com or by calling (817) 410-2140.
About Integrated BioPharma Inc (INB)
Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company's biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at http://www.iBioPharma.com.
Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.